Company intelligence / Profile preview

UnicoCell Biomed Co., Ltd.

Ownership: Private
Employees: ~31
Development stage: Phase 3

Overview

ELIXCYTE®, an adipose-derived MSC therapy, has reached Phase 3 recruitment for knee OA and completed Phase 1/2 trials in CKD. The company’s allogeneic cell bank has US FDA Drug Master File acknowledgment. Their secretome/exosome platform won national innovation awards. They are also a certified supplier of autologous stem cell drugs to hospitals in Taiwan for OA and wound healing under special regulations

Therapeutic areas: DermatologyRheumatologyNephrology
Modalities: Adipose-derived mesenchymal stem cells (MSCs)autologous stem cell transplantationallogeneic stem cell bankexosomes/secretome/conditioned medium
Industry: Biotech

Drug pipeline

1 asset

elixcyte

Partnerships

Mentor Group strategic alliance announced Feb.2025partnerships with hospitals in Taiwan for clinical application of autologous/adipose stem cells under special medical regulations

Beyond the preview

Go deeper on UnicoCell Biomed Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UnicoCell Biomed Co., Ltd..

Explore the full profile